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Aims In the last decade, several approaches to ablating triggers and substrates of atrial fibrillation (AF) have been
developed. However, most studies have reported data only on short- or medium-term follow-up. The aim of this
study was to investigate whether the 1-year efficacy of catheter ablation for AF is predictive of long-term clinical
success.
Methods
and results
Between February 2001 and October 2003, 229 consecutive patients affected by drug-refractory paroxysmal or per-
sistent AF underwent a single radiofrequency catheter ablation procedure (anatomical approach in 146 patients and
electrophysiologically guided approach in 83 patients). Of these patients, 177 (mean age 59.1+10.5 years, 57.6%
with paroxysmal AF) were free from any atrial arrhythmia recurrence after 12 months. These 177 patients were sub-
sequently followed up for at least another 24 months, by means of electrocardiogram and 24 h Holter monitoring.
After a mean follow-up of 49.7+ 13.3 months (range 36–83 months), 58.2% of the patients were free from any atrial
arrhythmia recurrence (39.5% without antiarrhythmic drugs). The actuarial atrial arrhythmia recurrence rate was
13.0% at 2 years, 21.8% at 3 years, 35.0% at 4 years, 46.8% at 5 years, and 54.6% at 6 years. Atrial arrhythmia-
free survival was similar in patients with paroxysmal or persistent AF, with and without antiarrhythmic drugs
during the follow-up, who underwent electrophysiologically guided pulmonary vein (PV) isolation or anatomical
PV ablation.
Conclusion Even patients in whom catheter ablation prevents AF recurrence for 1 year should not be considered ‘cured’, since
.40% of them will suffer AF recurrence over a long-term clinical follow-up.
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Introduction
The discovery of the role of the pulmonary veins (PVs) in initiating
and perpetuating atrial fibrillation (AF) has led to the ablative treat-
ment of AF.1 –2 In the last decade, several approaches3– 6 to ablat-
ing triggers and substrates of AF have been developed, all of which
have proved able to prevent AF recurrence in up to 80–90% of
patients. However, most studies have reported data only on
short- or medium-term follow-up, usually no longer than
12 months. Atrial fibrillation is linked to age-related physiological
modifications of atrial anatomy. Thus, unlike arrhythmias related
to inherited substrates, such as Kent fibres or dual atrioventricular
pathway, in which short-term success correlates very well with
long-term outcome, in the case of AF, this correlation may not
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be true. The aim of this retrospective study was to evaluate
whether in patients with drug-refractory AF in whom catheter
ablation had prevented arrhythmia recurrence during the first
year of follow-up, the efficacy of catheter ablation persisted over
long-term follow-up.
Methods
Patient characteristics and study design
Between February 2001 and October 2003, 229 consecutive patients
affected by drug-refractory paroxysmal or persistent AF underwent
radiofrequency (RF) catheter ablation (electro-anatomical approach
in 146 patients and electrophysiologically guided approach in
83 patients) in three Italian centres. Paroxysmal AF was defined as
self-terminating AF episodes lasting ,7 days. Persistent AF was
defined as AF episodes lasting 7 days or requiring pharmacological
or electrical cardioversion because of intolerable symptoms.7 Patients
with permanent AF, i.e. AF as the sole rhythm for the last 6 months,
were not included in this study. Of these 229 patients, 177 (78%)
remained free from any atrial arrhythmia recurrence, both AF and
atrial flutter, during a 12-month follow-up after a single ablation.
This group was further followed up for at least 24 months, and the
incidence of atrial arrhythmia recurrence was evaluated. This observa-
tional study was approved by each institutional review committee, and
all patients provided written informed consent for the ablation
procedure.
Electrophysiological study and catheter
ablation
Prior to electrophysiological study, transoesophageal echocardiogra-
phy was performed in order to exclude left atrial (LA) thrombus. All
patients received effective oral anticoagulation (international normal-
ized ratio between 2 and 3) for 1 month before ablation. Heparin
anticoagulation replaced oral anticoagulants 72 h before ablation
and was discontinued 4 h before the procedure. Patients were
studied in a conscious state, a bolus of pethidine hydrochloride, mida-
zolam, or propofol being administered in the event of intolerable pain
during ablation. A quadripolar or decapolar catheter was inserted
through the femoral, jugular, subclavian, or antecubital vein into the
coronary sinus. In all patients, the LA and PVs were explored by
means of a trans-septal approach. After trans-septal puncture, an intra-
venous bolus of heparin (5000 IU) was administered, followed by infu-
sion or additional boluses to maintain an activated clotting time
250 s.
In patients who underwent the electro-anatomical approach, real-
time 3D LA maps were reconstructed by using a non-fluoroscopic
navigation system (CARTOTM, Biosense Webster Inc., Diamond Bar,
CA, USA). Maps were acquired during AF or pacing from the coronary
sinus, as described previously.8 Radiofrequency pulses were delivered
by using the mapping catheter (NavistarTM, Biosense Webster Inc.)
(8 mm tip with a temperature setting of 608C and RF energy up to
70 W, or 3.5 mm irrigated-tip catheter with a temperature setting up
to 458C, RF energy up to 40 W, and an irrigation rate up to 30 mL/
min). Radiofrequency energy was delivered for up to 120 s until
local electrogram amplitude was reduced by 80%. The ablation
lines consisted of contiguous focal lesions deployed at a distance of
5 mm from the ostia of the PVs in order to create a circumferential
line around each PV. Another ablation line was created by connecting
the left inferior PV to the mitral annulus (mitral isthmus). The endpoint
of the PV ablation was low peak-to-peak bipolar potentials (,0.1 mV)
inside the lesion, as revealed by local electrogram analysis and voltage
maps. A minimum of five points for each circumferential line were
sampled. If sites of high voltage (.0.1 mV) were still present,
additional ablations were performed, both along and within the encir-
cling ablation lines. The endpoint of mitral isthmus line ablation was
evaluated by pacing from the distal electrodes of the coronary sinus
catheter and recording on the distal electrodes of the ablation cath-
eter, positioned on that line, a double potential with an isoelectric
line of at least 80 ms.
In patients who underwent the electrophysiological approach, two
catheters were inserted into the LA: a multipolar steerable circular
catheter for circumferential PV mapping (LASSO
TM
, Biosense
Webster Inc.), and an 8 mm tip catheter (Celsius dual temperature,
Biosense Webster Inc.) or an irrigated 3.5 mm tip catheter (Thermo-
CoolTM, Biosense Webster, Inc.) for ablation. After entering the PV,
the circular catheter was positioned as close as possible to the PV
ostium. Pulmonary vein isolation was obtained by delivering RF
energy to those ostial sites which showed electrical breakthroughs.3
Radiofrequency was applied in a temperature-control mode with a
temperature setting up to 608C and RF energy up to 70 W while
using an 8 mm tip ablation catheter, and in a power-control mode
with RF energy up to 35 W while using an irrigated-tip catheter. The
endpoint of the ablation procedure was PV isolation, as documented
by the disappearance or disconnection of PV potentials. Cavotricuspid
isthmus ablation was performed at the end of LA ablation in all
patients, apart from those in whom it had been performed during a
previous procedure. Patients who were still in AF at the end of ablation
underwent electrical cardioversion before cavotricuspid isthmus
ablation.
Post-ablation management
All patients were discharged on oral anticoagulants and continued their
antiarrhythmic drugs for at least 3 months. Transoesophageal and
transthoracic echocardiography was performed after 3 months to
assess PV stenosis, mitral valve function, and left ventricular ejection
fraction. Clinical examination, electrocardiogram (ECG), and 24 h
Holter monitoring were performed after 3, 6, and 12 months. Patients
in stable sinus rhythm after the first 6 months were encouraged to dis-
continue antiarrhythmic drugs. Patients who maintained sinus rhythm,
with or without antiarrhythmic drugs, for the 12-month follow-up
period constituted the study group. These patients continued to be
monitored every 6 months by means of outpatient clinical examin-
ations, ECG, and 24 h Holter monitoring for at least another
24 months. The primary endpoint of the study was experience/
detection of any atrial arrhythmias lasting .30 s, on or off
antiarrhythmic drugs, after a single ablation procedure.
Statistical analysis
Continuous measurements were expressed as mean+ SD and were
compared by means of Student’s t-test. The normality of distribution
of continuous variables was assessed by visual inspection of the histo-
grams. Discrete variables were analysed by x2 or Fisher’s exact test;
relative risk and 95% confidence interval were calculated. Single-
variable Cox’s regression analysis was used for the search of predictors
of sinus rhythm maintenance. Variables with P, 0.3 on univariate
analysis were fitted into a multivariate non-linear regression model.
A Kaplan–Meier analysis with the log-rank test was used to determine
the probability of freedom from AF recurrence. All tests were two-
tailed. A P-value ,0.05 was considered statistically significant. Analysis
was performed by means of the Statistical Package for the Social
Sciences (SPSS, version 11.0) (SPSS, Inc., Chicago, IL, USA).
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Results
Clinical and procedural characteristics
Clinical characteristics of the 177 study patients are shown in
Table 1. Of note, most suffered from paroxysmal AF and had a
long arrhythmic history. Although 42.9% presented a structural
heart disease—hypertensive cardiopathy in most cases—the left
ventricular ejection fraction was within the normal limit, and the
left atrium only mildly dilated.
Most of our patients (110/177, 62.1%) underwent electro-
anatomical ablation, whereas electrophysiologically guided ablation
was performed in 67/177 (37.9%). Inferior vena cavotricuspid
annulus isthmus ablation was performed, in the same session, in
61/177 patients (34.5%).
Clinical outcome
Patients were followed up for a mean of 49.7+ 13.3 months
(range 36–83 months). Five deaths (2.8%) occurred: two non-
cardiovascular deaths and three cardiovascular deaths, all sudden.
During follow-up, AF recurred in 74/177 patients (41.8%). We
did not observe atrial tachyarrhythmias other than AF. Paroxysmal
AF was the most frequent type of recurrent AF (38 patients,
21.5%), followed by permanent AF (20 patients, 11.3%), and per-
sistent AF (16 patients, 9.0%). The evolution of AF in patients
with recurrences is presented in Figure 1.
The actuarial atrial arrhythmia recurrence rate was 13.0% at
2 years, 21.8% at 3 years, 35.0% at 4 years, 46.8% at 5 years,
and 54.6% at 6 years (Figure 2).
In 33 patients (18.6%), sinus rhythm was maintained on anti-
arrhythmic drugs (amiodarone in 16 patients, flecainide in 8, pro-
pafenone in 5, and sotalol in 4). The actuarial curves of freedom
from AF, with and without antiarrhythmic drugs, are presented
in Figure 3. The cumulative probability of maintaining sinus
rhythm did not prove significantly different between these two
groups of patients.
Predictors of atrial fibrillation-free
survival
Of several clinical and procedural variables considered, none
proved to be correlated with long-term maintenance of sinus
rhythm (Table 2) at both univariate and multivariate analysis. We
observed only a trend towards a better result in patients with a
small LA. Specifically, the cumulative probability of sinus rhythm
maintenance was not significantly different between patients with
paroxysmal AF and those with persistent AF (Figure 4), nor
between patients who underwent electrophysiologically guided
PV isolation and those who underwent anatomical PV ablation
(Figure 5).
Discussion
Main findings
This observational retrospective study evaluated the long-term
outcome of a large multicentre series of consecutive patients
with drug-refractory AF who underwent a single catheter ablation
procedure. Approximately 40% of the patients who were free
from any arrhythmia recurrence 1 year after ablation suffered AF
recurrence during the next 3 years. The efficacy of electrophysio-
logically guided PV isolation and anatomical PV ablation proved to
be similar. Atrial fibrillation-free survival was similar in patients with
paroxysmal AF and in those with persistent AF, and in patients on
or off antiarrhythmic drugs.
Long-term efficacy of atrial
fibrillation ablation
Although catheter ablation of AF has emerged as an important
treatment option for patients with symptomatic AF,9 –11 its long-
term safety and efficacy are still unknown.12– 13 The large
number of anatomical and electrophysiological substrates that
initiate and/or maintain AF,14 and their physiological modification
with ageing, makes it unlikely that short-term success will correlate
with long-term outcome. So far, few studies have investigated what
happens after the first 12 months following AF ablation,15– 22 and
only three have involved a mean follow-up longer than
3 years.19,21,22 Katritsis et al.19 followed up 39 patients suffering
from paroxysmal AF for 42.2+ 6.0 months after segmental PV iso-
lation. Fiala et al.21 reported the results of a randomized study on
paroxysmal AF ablation in which they compared two different
techniques (segmental PV isolation and circumferential PV iso-
lation) in 110 patients, who were followed up for a mean of
48+8 months after ablation. What is striking is the different clini-
cal outcome observed in these two studies, even though the popu-
lations studied were similar and the follow-up duration was the
same. In the study of Katritsis et al., long-term success without anti-
arrhythmic drugs after a single ablation procedure was very poor
(8%), whereas Fiala et al. reported that 56% of the patients were
free from arrhythmia after the first ablation, without anti-
arrhythmic drugs. This significant discrepancy cannot be explained
in terms of ablation technique, as in Fiala et al.’s study, the long-
term success rate was similar for the two techniques: segmental
PV isolation and circumferential PV isolation. Intermediate data
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Clinical characteristics
n5 177
Male (%) 74.6
Age (years) 59.1+10.5
Paroxysmal AF (%) 57.6
AF duration (years) 5.3+3.8
SHD (%) 42.9
Hypertensive HD (%) 31.7
Dilated cardiomyopathy (%) 5.5
Ischemic HD (%) 3.5
Valvular HD (%) 2.2
Left atrial size (mm) 46.1+4.3
LVEF (%) 57.7+6.6
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; SHD, structural heart
disease.
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were reported by Gaita et al.22 In their study, 204 consecutive
patients symptomatic for paroxysmal or persistent/permanent AF
were randomly assigned to two different ablation schemes: PV iso-
lation or PV isolation plus left linear lesions. Among patients with
paroxysmal AF who had undergone a single procedure, 29% of
those treated with PV isolation and 53% of those treated with
PV isolation plus left linear lesions maintained sinus rhythm over
a 3-year follow-up. Among patients with persistent/permanent
AF, only 19% of those treated with PV isolation maintained sinus
rhythm over the 3-year follow-up, whereas 41% of the patients
Figure 1 Type of AF in patients in whom arrhythmias recurred during follow-up. (A) Patients who presented paroxysmal AF before ablation.
(B) Patients who presented persistent AF before ablation.
Figure 2 Kaplan–Meier estimation of the time to AF occur-
rence after ablation in the total study group.
Figure 3 Kaplan–Meier estimation of the time to AF occur-
rence after ablation in patients on or off antiarrhythmic drugs.
Solid line indicates patients on antiarrhythmic drugs and dotted
line indicates those not on antiarrhythmic drugs.
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treated with PV isolation plus left linear lesions achieved this
result.22
In our study, 58.2% of the patients were free from arrhythmia
after 4 years (45% of the original 229 patients), 18.6% of whom
continued antiarrhythmic therapy. These results seem to confirm
those of Fiala et al.21 and Gaita et al.22 What is new in our data
is that for the first time, no difference in the AF recurrence rate
emerged between paroxysmal and persistent AF patients over a
very long time after a single ablation procedure. Although the
efficacy of PV ablation in persistent AF patients is less predictable,
a better long-term outcome of PV isolation may be expected in
paroxysmal AF patients, in whom the role of triggers is apparently
predominant. Our findings, however, seem not to support this
hypothesis. Of note, during a mean follow-up of 4 years,
11.2% of our patients who underwent ablation for persistent or
paroxysmal AF evolved to permanent AF. A similar rate of pro-
gression to permanent AF was reported in the Olmsted County
study by Jahangir et al.23 In their study, in a cohort of 71 patients
with lone paroxysmal (n ¼ 34) or persistent AF (n ¼ 37) treated
with antiarrhythmic drugs, 7 patients (9.9%) suffered progression
to permanent AF within 5 years. Comparison of the results of
the two studies suggests that a single procedure of catheter abla-
tion is unable to prevent progression to permanent AF. Organized
atrial arrhythmias are reported to occur in 3–10% of the patients
after PV ablation.24–26 In contrast to these findings, we did not
observe any organized atrial arrhythmias after the first 12 post-
ablation months. However, all previous reports regarding post-
ablation atrial flutter or tachycardias refer to short-term follow-up.
On increasing the duration of follow-up, the rate of these arrhyth-
mias seems to decrease.19,21,22
Predictors of long-term sinus rhythm
maintenance
Our findings did not allow us to identify any predictors of very
long-term sinus rhythm maintenance. We only observed that
patients with an enlarged LA had a lower probability of maintaining
sinus rhythm; this could be confirmed by increasing the number of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Predictors of sinus rhythm maintenance:
univariate analysis
Atrial
fibrillation
(n 5 74)
Sinus
rhythm
(n 5 103)
P-value
Age (years) 58.5+10.6 59.5+10.5 0.52
Male gender (%) 62.2 56.8 0.53
SHD (%) 61.4 53.9 0.32
Paroxysmal AF (%) 56.0 59.8 0.61
Left atrial size (mm) 46.7+4.4 45.6+4.2 0.08
LVEF (%) 57.2+6.5 58.0+6.8 0.47
Electro-anatomical
ablation (%)
65.7 53.6 0.12
Right isthmus ablation
(%)
62.1 50.8 0.15
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; SHD, structural heart
disease.
Figure 4 Kaplan–Meier estimation of the time to AF occur-
rence after ablation in patients with paroxysmal or persistent
AF. Solid line indicates patients with paroxysmal AF and dotted
line indicates those with persistent AF.
Figure 5 Kaplan–Meier estimation of the time to AF occur-
rence after ablation in patients who underwent anatomical
pulmonary vein ablation or electrophysiologically guided pulmon-
ary vein isolation. Solid line indicates anatomical pulmonary vein
ablation and dotted line indicates electrophysiologically guided
pulmonary vein isolation.
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study patients. No other study has investigated this issue in the
setting of very late recurrences, although Shah et al.20 found that
hypertension and hyperlipaemia characterized patients with late
recurrences among 264 patients followed up for a shorter
period (28+12 months).
Study limitations
An important limitation is that this was an observational study.
Nevertheless, observational studies like this can provide additional
information, since they are fully representative of actual clinical
practice, in which several factors that are underestimated in pro-
spective trials, such as the different experience of the centres
involved, may play a role. For this reason, observational studies
will be of particular importance in monitoring and guiding the
incorporation of this therapeutic procedure into clinical practice.
The cumulative probability of sinus rhythm maintenance did not
prove significantly different between patients who underwent elec-
trophysiologically guided PV isolation and those who underwent
anatomical PV ablation. However, the fact that our experience
with electrophysiologically guided PV isolation was shorter than
that with anatomical PV ablation might have affected this result.
To asses the block along the mitral isthmus, we used only the
presence of widely separated local double potentials along the
length of the ablation line during coronary sinus pacing, and not
also the mapping of the activation detour during pacing from
either side of the line and the differential pacing to distinguish
slow conduction across the isthmus from complete block, as
described by Jais et al.27 Our technique might have overestimate
the percentage of patients in which the bidirectional block was
really achieved thus increasing the probability of LA flutter recur-
rences after ablation. However, this limitation should have not
influenced our long-term results since we decided to evaluate
the outcome only of patients free of any arrhythmia, both AF
and atrial flutter, after 1-year of follow-up.
Another potential limitation is that 33 of our patients (18.6%)
who remained in sinus rhythm were on antiarrhythmic drugs.
However, the cumulative probability of sinus rhythm maintenance
did not prove significantly different between patients on anti-
arrhythmic drugs and those not on such drugs. Similar data have
recently been reported by Turco et al.,28 who observed that con-
tinuing antiarrhythmic drug therapy did not lower AF recurrences
after catheter ablation for AF, whereas antiarrhythmic drugs
increased the proportion of patients with asymptomatic AF
episodes.
Conclusions
Data from published studies and from our experience seem to
confirm that success over a 12-month follow-up does not necess-
arily guarantee permanent success, and that the early hope of AF
ablation being a ‘curative’ procedure continues to be shattered
by the harsh reality that AF does in fact recur after a several-month
blanking period.29 Thus, AF ablation seems to have a ‘palliative’
rather than ‘curative’ effect, at least in most patients. This fact
raises concerns about the risk of discontinuing anticoagulation
after short-term success in patients with risk factors for
thrombo-embolic events. Multiple ablation procedures might
increase the long-term rate of patients free from AF.22
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